Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash from Investing Activities: 2020-2024

Historic Cash from Investing Activities for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to -$44.5 million.

  • Monte Rosa Therapeutics' Cash from Investing Activities rose 1.03% to $38.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$67.7 million, marking a year-over-year decrease of 9231.31%. This contributed to the annual value of -$44.5 million for FY2024, which is 150.06% down from last year.
  • Monte Rosa Therapeutics' Cash from Investing Activities amounted to -$44.5 million in FY2024, which was down 150.06% from $88.8 million recorded in FY2023.
  • In the past 5 years, Monte Rosa Therapeutics' Cash from Investing Activities registered a high of $88.8 million during FY2023, and its lowest value of -$219.2 million during FY2022.
  • In the last 3 years, Monte Rosa Therapeutics' Cash from Investing Activities had a median value of -$44.5 million in 2024 and averaged -$58.3 million.
  • Per our database at Business Quant, Monte Rosa Therapeutics' Cash from Investing Activities plummeted by 2,170.99% in 2022 and then surged by 140.51% in 2023.
  • Over the past 5 years, Monte Rosa Therapeutics' Cash from Investing Activities (Yearly) stood at -$3.4 million in 2020, then crashed by 184.83% to -$9.7 million in 2021, then slumped by 2,170.99% to -$219.2 million in 2022, then spiked by 140.51% to $88.8 million in 2023, then plummeted by 150.06% to -$44.5 million in 2024.